Publications by Topic

Budnitz DS, Shehab N, Lovegrove MC, Geller AI, Lind JN, Pollock DA. U.S Department Emergency Visits Attributed to Medication Harms, 2017-2019external icon. JAMA 2021;326(13):1299-1309.
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-2014.external icon JAMA 2016;316(20):2115-2125.
Jhung MA, Budnitz DS, Mendelsohn AB, Weidenbach KN, Nelson TD, Pollock DA. Evaluation and overview of the national electronic injury surveillance system-cooperative adverse drug event surveillance project (NEISS-CADES)external icon. Medical Care 2007;45 (suppl 2):S96-S102.
Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug eventsexternal icon. JAMA 2006;296:1858-66.
Budnitz DS, Pollock D, Mendelsohn AB, Weidenbach KA, McDonald AK, Annest JL. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance systemexternal icon. Ann Emerg Med 2005;45:197-206.
Assessing the national electronic injury surveillance system – cooperative adverse drug event surveillance project – six sites, United States, January 1-June 15, 2004external icon. MMWR Morb Mortal Wkly Rep 2005;54:380-3.

Budnitz DS, Lovegrove MC, Geller R. Prevention of unintentional medication overdose among children: Time for the promise of the Poison Prevention Packaging Act to come to fruitionexternal icon. JAMA 2020;324(6):550-551.
Budnitz D, Malani PN. Keeping medicine away from childrenexternal icon. JAMA 2020; 324:614.
Hampp C, Lovegrove MC, Budnitz DS, Mathew J, Ho A, McAninch J. The role of unit-dose child-resistant packaging in unintentional childhood exposures to buprenorphine-naloxone tabletsexternal icon. Drug Saf 2020 Feb;43(2):189–91.
Agarwal M, Lovegrove MC, Geller RJ, Pomerleau AC, Sapiano MRP, Weidle NJ, Morgan BW, Budnitz DS. Circumstances involved in unsupervised solid dose medication exposures among young childrenexternal icon. J Pediatr 2020 Apr;219:188–95.e6.
Hampp C, Lovegrove MC, Budnitz DS, Mathew J, Ho A, McAninch J. The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tabletsexternal icon. Drug Saf 2020 Feb;43(2):189–91.
Lovegrove MC, Geller AI, Fleming-Dutra KE, Shehab N, Sapiano MR, Budnitz DS. U.S. Emergency Department Visits for Adverse Drug Events From Antibiotics in Children, 2011-2015.external icon J Pediatric Infect Dis Soc 2018 Aug; doi: 10.1093/jpids/piy066.
Lovegrove MC, Weidle NJ, Budnitz DS. Ingestion of Over-the-Counter Liquid Medications: Emergency Department Visits by Children Aged Less Than 6 Years, 2012-2015.external icon Am J Prev Med 2019 Feb;56(2):288-292.
Lovegrove MC, Sapiano MRP, Paul IM, Yin HS, Wilkins TL, Budnitz DS. Primary Care Provider Perceptions and Practices Regarding Dosing Units for Oral Liquid Medications.external icon Acad Pediatr 2017 Dec; doi: 10.1016/j.acap.2017.12.002.
Budnitz D, Lovegrove M, Sapiano M, Mathew J, Kegler S, Geller A, Hampp C. Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion — United States, 2008-2015. MMWR Morb Mortal Wkly Rep 2016 Oct;65(41):1148-1149.
Budnitz DS, Lovegrove MC, Rose KO. Adherence to label and device recommendations for over-the-counter pediatric liquid medicationsexternal icon. Pediatrics 2014;133:e283-90.
Emergency department visits and hospitalizations for buprenorphine ingestion by children – United States, 2010-2011. MMWR Morb Mortal Wkly Rep 2013;62:56. (Reprinted in JAMA 2013;309:1667-8.)
Hampton LM, Nguyen DB, Edwards JR, Budnitz DS. Cough and cold medication adverse events after market withdrawal and labeling revisionexternal icon. Pediatrics 2013;132:1047-54.
Lovegrove MC, Hon S, Geller RJ, Rose KO, Hampton LM, Bradley J, Budnitz DS. Efficacy of flow restrictors in limiting access of liquid medications by young childrenexternal icon. J Pediatr 2013;163:1134-9.e1.
Budnitz DS, Lovegrove MC. The last mile: taking the final steps in preventing pediatric pharmaceutical poisoningsexternal icon. J Pediatr 2012;160:190-2.
Budnitz DS, Salis S. Preventing medication overdoses in young children: an opportunity for harm eliminationexternal icon. Pediatrics 2011;127:e1597-9.
Shehab N, Schaefer MK, Kegler SR, Budnitz DS. Adverse events from cough and cold medications after a market withdrawal of products labeled for infantsexternal icon. Pediatrics 2010;126:1100-07.
Budnitz DS, Lewis LL, Shehab N, Birnkrant D. CDC and FDA response to risk of confusion in dosing Tamiflu oral suspensionexternal icon. N Engl J Med 2009;361:1913-4.
Schillie SF, Shehab N, Thomas KE, Budnitz DS. Medication overdoses leading to emergency department visits among childrenexternal icon. Am J Prev Med 2009;37:181-7.
Cohen AL, Budnitz DS, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N, Pollock DA. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescentsexternal iconn. J Pediatr 2008;152:416-21.
Schaefer MK, Shehab N, Cohen AL, Budnitz DS. Adverse events from cough and cold medications in childrenexternal icon Pediatrics 2008;121:783-7.
Infant deaths associated with cough and cold medications – two states, 2005. MMWR Morb Mortal Wkly Rep 2007;56:1-4.
Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorderexternal icon.N Engl J Med 2006;354:2294-5.
Nonfatal, unintentional medication exposures among young children, United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2006;55:1-5. (Reprinted in JAMA 2006;295:882-4.)

Shehab N, Ziemba R, Campbell KN, Geller AI, Moro RN, Gage BF, Budnitz DS, Yang TH. Assessment of ICD-10-CM Code Assignment Validity for Case Finding of Outpatient Anticoagulant-Related Bleeding Among Medicare Beneficiariesexternal icon. Pharmacoepidemiol Drug Saf 2019 Jul;28(7):951-964.
Budnitz DS, Lovegrove ML, Shehab N. Reply – Emergency hospitalizations for adverse drug events in older Americansexternal icon. N Engl J Med 2012;366:859-60.
Budnitz DS, Lovegrove MC, Shehab N, Richards, CL. Emergency hospitalizations for adverse drug events in older Americansexternal icon. [PDF – 522 KB] N Engl J Med 2011; 365:2002-12.
Shehab N, Budnitz DS. Time to change the paradigm–from potentially inappropriate to real patient harms.external icon. Arch Intern Med 2011;171:473-4.
Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillanceexternal icon. Jt Comm J Qual Patient Saf 2010;36:12-21.
Budnitz DS. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing–invited commentaryexternal icon Arch Intern Med 2009;169:1332-4.
Budnitz DS. Inappropriate medication use in hospitalized older adults–is it time for interventions?external icon J Hosp Med 2008;3:87-90.
Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adultsexternal icon. Ann Intern Med 2007;147:755-65.

Lee JT, Althomsons SP, Wu H, Budnitz DS, Kalayil EJ, Lindley MC, Pingali C, Bridges CB, Geller AI, Fiebelkorn AP, Graitcer SB, Singleton JA, Patel SA. Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category, National Healthcare Safety Network – United States, March 2021. MMWR Morb Mortal Wkly Rep 2021 Jul 30;70(30):1036-1039.
Lind JN, Lovegrove MC, Geller AI, Uyeki TM, Datta DS, Budnitz DS. Increase in outpatient ivermectin dispensing in the United States during the COVID-19 Pandemic: a cross-sectional analysisexternal icon. J Gen Intern Med 2021 Jun 18;1-3
Geller AI, Lovegrove MC, Lind JN, Datta SD, Budnitz DS. Assessment of Outpatient Dispensing of Products Proposed for Treatment or Prevention of COVID-19 by US Retail Pharmacies During the Pandemicexternal icon. JAMA Intern Med 2021 Jun 1;181(6):869-872.
Gouin KA, Creasy S, Beckerson M, Wdowicki M, Hicks LA, Lind JN, Geller AI, Budnitz DS, Kabbani S. Trends in prescribing of antibiotics and drugs Investigated for COVID-19 Treatment in US Nursing Home residents during the COVID-19 pandemicexternal icon. Clin Infect Dis 2021 Mar 10;ciab225.
Acosta AM, Mathis AL, Budnitz DS, Geller A, Chai, Alden MB, et al. COVID-19 investigational treatments in use among hospitalized patients identified through the U.S. Coronavirus Disease 2019 -Associated Hospitalization Surveillance Network, March 1–June 30, 2020external icon. Open Forum Infect Dis 2020;7:1-5.
Bull-Otterson L, Gray EB, Strosnider HM, Schieber LZ, Budnitz DS, Courtney J, Garcia MC, Brooks JT, MacKenzie WR, Gundlapalli AV. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020. MMWR Morb Mortal Wkly Rep 2020;69:1210-5.
Shehab N, Lovegrove MC, Budnitz DS. US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, United States, October 2019 – March 2020external icon. JAMA Intern Med 2020 2020;180:1384-6.
Geller AI, Lovegrove MC, Shehab N, Hicks LA, Sapiano MRP, Budnitz DS. National Estimates of Emergency Department Visits for Antibiotic Adverse Events Among Adults-United States, 2011-2015.external icon J Gen Intern Med 2018 Jul;33(7):1060-1068.
Jones SC, Budnitz DS, Sorbello A, Mehta H. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactionsexternal icon. Pharmacoepidemiol Drug Saf 2013;22:1099-106.
Lovegrove MC, Shehab N, Hales CM, Poneleit K, Crane E, Budnitz DS. Emergency department visits for antiviral adverse events during the 2009 H1N1 influenza pandemicexternal icon. Public Health Rep 2011;126:312-7.
Editorial commentary: antibiotics for treatment of acute respiratory tract infections: decreasing benefit, increasing risk, and the irrelevance of antimicrobial resistanceexternal icon. Clin Infect Dis 2008;47:744-6.
Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse eventsexternal icon. Clin Infect Dis 2008;47:735-43.

See I, Gokhale RH, Geller AI, Lovegrove MC, Schranz A, Flischauer A, McCarthy N, Baggs J, Fiore A. National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Reviewexternal icon. J Infect Dis 2020 Sep 2;222(Suppl 5):S429-S436.
Tanwar S, Geller AI, Lovegrove MC, Budnitz DS. Notes from the Field: Emergency Visits for Complications of Injecting Transmucosal Buprenorphine Products – United States, 2016-2018. MMWR Morb Mortal Wkly Rep 2020 Aug 14;69(32):1102–3.
Lovegrove MC, Dowell D, Geller AI, Goring SK, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Acute Harms From Prescription Opioid Use, 2016-2017.external icon Am J Public Health 2019 May;109(5):784-791.
Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalitiesexternal icon. JAMA 2008;300:2613-20.
Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United Statesexternal icon. Pharmacoepidemiol Drug Saf 2006;15:618-27.
Ballesteros MF, Budnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolinaexternal icon. JAMA 2003;290:40.

Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of acetaminophen-containing productsexternal icon. Am J Prev Med 2011;40:585-92
Manthripragada AD, Zhou EH, Budnitz DS, Lovegrove MC, Willy ME. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United Statesexternal icon. Pharmacoepidemiol Drug Saf 2011;doi: 10.1002/pds.2090.
Willy M, Kelly JP, Nourjah P, Kaufman DW, Budnitz DS, Staffa J. Emergency department visits attributed to selected analgesics, United States, 2004-2005external icon. Pharmacoepidemiol Drug Saf 2009;18:188-95.

Geller AI, Conrad AO, Weidle NJ, Mehta H, Budnitz DS, Shehab N. Outpatient insulin-related adverse events due to mix-up errors: findings from two national surveillance systems, United States, 2012-2017external icon. Pharmacoepidemiol Drug Saf 2021 May;30(5):573–81.
Geller AI, Shehab N, Lovegrove MC, Rose KO, Weidle NJ, Goring SK, Budnitz DS. Emergency Visits for Oral Anticoagulant Bleedingexternal icon. J Gen Intern Med 2020 Jan;35(1):371-373.
Santos CAQ, Conover C, Shehab N, Geller AI, Guerra YS, Kramer H, Kosacz NM, Zhang H, Budnitz DS, Trick WE. Electronic Measurement of a Clinical Quality Measure for Inpatient Hypoglycemic Events: A Multicenter Validation Studyexternal icon. Med Care 2020 Oct;58(10):927-933.
Moro RN, Geller AI, Weidle NJ, Lind JN, Lovegrove MC, Rose KO, Goring SK, McAninch J, Dowell D, Budnitz DS. Emergency department visits Attributed to adverse events involving benzodiazepines, 2016-2017external icon. Am J Prev Med 2020 Apr;58(4):526–35.
Geller AI,Zhou EH, Budnitz DS, Lovegrove MC, Dal Pan GJ. Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA drug safety communicationsexternal icon. Pharmacoepidemiol Drug Saf 2020 Mar;29(3):352–6.
Punzalan C, Budnitz DS, Chirtel SJ, Geller AI, Jones OE, Mozersky RP, Wolpert B. Swallowing Problems and Dietary Supplements: Data From U.S. Food and Drug Administration Adverse Event Reports, 2006-2015external icon. Ann Intern Med 2019 Aug; doi: 10.7326/M19-0947.
Geller AI, Dowell D, Lovegrove MC, McAninch JK, Goring SK, Rose KO, Weidle NJ, Budnitz DS. U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.external icon Am J Prev Med 2019 May;56(5):639-647.
Shehab N, Greenwald JL, Budnitz DS. Anticoagulation Across Care Transitions: Identifying Minimum Data to Maximize Drug Safety.external icon Jt Comm J Qual Patient Saf 2018 Nov;44(11):627-629.
Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, Budnitz DS. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizationsexternal icon. JAMA Intern Med 2014;174:678-86.
See I, Shehab N, Kegler SR, Laskar SR, Budnitz DS. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010external icon. Circ Heart Fail 2014;7:28-34.
Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarinexternal icon. Arch Intern Med 2010; 170:1926-33.

Top of Page

Page last reviewed: October 25, 2021

Content source: Centers for Disease Control and Prevention